ClinicalTrials.gg
RecruitingNCT05463380EuCARE-HOSPUpdated Aug 29, 2024

Hospitalised COVID-19 Patients Cohort Study in the EuCARE Project

An observational study in COVID-19, sponsored by Euresist Network GEIE. Recruiting at 10 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Euresist Network GEIE · Observational

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
22,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 392 studies in COVID-19 with a site in Italy — 37 open to participants now, 46 under way, 7 of them phase 3. COVID-19 · Italy.

Planned enrollment
2nd of 238
22,000 · median 251
Started
2022
with 35 others
Observational
238 of 392
24 open now
Primary completion
2026-10
later than 31 of 45 live
Registered
319th of 392
by date

Among the 392 studies in COVID-19 with a site in Italy, this one is the 2nd largest by planned enrollment of the 238 observational ones that give a count, is one of 36 that started in 2022, is one of 238 observational ones, reaches primary completion later than 31 of the 45 other live ones, and was the 319th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

37 of the 392 studies in COVID-19 with a site in Italy are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 392 studies in COVID-19 with a site in Italy, or all of them as a file.
02

Study summary

The WP3 hospitalized cohort in EuCARE is an observational multicentre study including collection of retrospective (historical) and prospective data from hospitalized COVID-19 patients followed at 12 clinics from 11 countries from 4 continents. In a subset of patients, peripheral blood, viral isolates and/or viral sequences are collected for analysis in WP2 with regards to neutralising antibodies, cellular immunity and SARS-CoV-2 diagnostics. Data and results from analysis of biological material will be analysed by biostatistical methods and with artificial intelligence in WP5. This analysis will focus on the impact on clinical outcome of viral variants / viral sequences as well as the vaccines used and the vaccination schedules.

Read the detailed description

Background: Since the start of the COVID-19 pandemic, novel SARS-CoV-2 variants of concern have emerged, some of which have become largely dominant including the B.1.1.7 (alpha), the B.1.617 (delta) and more recently the B.1.1.529 (omicron). The clinical implications of the different variants in unvaccinated and vaccinated persons are still not adequately characterized. The detailed understanding of the interplay between the variants, vaccine immune responses and disease severity is still scarce.

Study objectives:

Overall objectives are:

  • to collect data and/or biological material from COVID-19 in-patients in a diverse setting of 12 clinics in 11 countries and 4 continents
  • to analyse the clinical course of COVID-19 in in-patients in relation to the viral characteristics
  • to analyse the clinical course of COVID-19 in in-patients in relation to vaccines used and vaccination schedules
  • to deliver recommendations for optimized clinical management and treatment with special consideration to viral characteristics and to used vaccines

Specific objectives are:

  • To describe the patterns of clinical symptoms, therapeutic interventions and clinical outcome in patients hospitalized from 12 hospitals/clinics, in 11 countries and 4 continents.
  • To assess the impact of viral variants / viral sequences on the clinical outcome measured as all-cause in-hospital mortality, non-invasive mechanical ventilation/high-flow nasal oxygen, mechanical ventilation, admission to intensive care unit, length of time in intensive care and overall length of hospitalization.
  • To assess the impact of different vaccines and vaccination schedules on the clinical outcome measured as all-cause in-hospital mortality, non-invasive mechanical ventilation/high-flow nasal oxygen, mechanical ventilation, admission to intensive care unit, length of time in intensive care and overall length of hospitalization.
  • To assess the impact of viral variants / sequences in response to treatment interventions and the associated clinical outcome
  • To assess the impact of different vaccines and vaccination schedules in response to treatment interventions and the associated clinical outcome
  • To provide WP2 in EuCARE with biological material for further studies on viral characteristics and associated immune responses
  • To provide WP5 in EuCARE with data for further studies using artificial intelligence
03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospitalized adult (>18 years) patients including patients in the emergency ward Positive for SARS-CoV-2 by PCR any time from 14 days before admission date until hospital discharge. Both first and recurrent episodes of COVID-19 will be included.

Eligibility criteria

Inclusion Criteria:

  • Hospitalized adult (>18 years) patients including patients in the emergency ward
  • Positive for SARS-CoV-2 by PCR any time from 14 days before admission date until hospital discharge. Both first and recurrent episodes of COVID-19 will be included.
  • Having a signed when required by ethical approval

Exclusion Criteria: none

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
22,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Hospitalized COVID 19 patients

    Hospitalized adult (\>18 years) patients including patients in the emergency ward Positive for SARS-CoV-2 by PCR any time from 14 days before admission date until hospital discharge. Both first and recurrent episodes of COVID-19 will be included. Having a signed informed consent when required by ethical approval

    Other: standard of care

Interventions

  • Otherstandard of care

    The patient will be treated following the satndard of care in the participating units

06

What researchers measure

Primary outcomes

  1. Severity of SARS-CoV-2 infection

    This is currently being discussed, which classification system should be used. This will be harmonized to recommendations by the WHO/ISARIC or other source.

    Time frame: through study completion, an average of 4 year

  2. In-hospital mortality

    YYYY-MM-DD or NA if discharged alive

    Time frame: through study completion, an average of 4 year

  3. ICU Admissions and Discharges

    YYYY-MM-DD or NA if not ICU-admitted

    Time frame: through study completion, an average of 4 year

  4. Rate of Invasive and Non invasive mechanical ventilation

    Yes/No/Unknown - If yes, duration of mechanical ventilation

    Time frame: through study completion, an average of 4 year

Secondary outcomes

  1. Frequency and type of Renal replacement therapies (RRT, dialysis)

    Yes/No/Unknown

    Time frame: through study completion, an average of 4 year

  2. Frequency of Blood transfusions

    Yes/No/Unknown

    Time frame: through study completion, an average of 4 year

  3. Frequency of ECMO Frequency of ECMO

    Yes/No/Unknown

    Time frame: through study completion, an average of 4 year

07

Study locations

10 of 10 sites recruiting
  • Heinrich-Heine-Universität Düsseldorf
    Düsseldorf, Germany
    Recruiting
    • Björn-Erik O. Jensen, PROF · Contact
  • ASST Santi Paolo e Carlo
    Milan, Lombardia, Italy
    Recruiting
    • ANTONELLA D'ARMINIO MONFORTE, PROF · Contact
  • University of Rome Tor Vergata
    Rome, Italy
    Recruiting
    • FRANCESCA CECCHERINI SILBERSTEIN · Contact
  • Kenya Medical Research Institute (KEMRI)
    Nairobi, Kenya
    Recruiting
    • Matilu Mwau · Contact
  • Vilnius universiteto ligoninė Santaros klinikos
    Vilnius, Lithuania
    Recruiting
    • DANIEL NAUMOVAS · Contact
  • Regional Hospital Dr. Juan Graham Casasús, Villahermosa
    Villahermosa, Mexico
    Recruiting
    • Jesus Arturo Ruiz Quiñones · Contact
  • Centro Hospitalar Lisboa Ocidental
    Lisboa, Portugal
    Recruiting
    • CRISTINA TOSCANO, PROF · Contact
  • Karolinska Institutet
    Stockholm, Sweden
    Recruiting
    • ANDERS Sönnerborg, Prof · Contact
    • ANDERS Sönnerborg, Prof · Principal investigator
  • Poole University Hospitals, Dorset
    Poole, United Kingdom
    Recruiting
    • FRANCIS Drobniewski · Contact
  • Bach Mai Hospital
    Hanoi, Vietnam
    Recruiting
    • Do Duy Cuong · Contact
08

References and documents

Individual participant data

Plan to share: Yes — The study is part of a project funded by the European Commission and the project agreement with the Commission affirms that the data and the results will be publi

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: AFTER THE STUDY END NO TIME LIMIT WAS FIXED

Access criteria: REQUEST TO THE STUDY COORDINATOR OR TO THE PROJECT PARTNERS

Data sharing details ↗ · eucareresearch.eu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Oct 2026, 55 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 55 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2022
First posted
Jul 19, 2022
StartActual
Feb 23, 2022
Primary completionEst.
Oct 13, 2026
CompletionEst.
Oct 13, 2026
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05463380
Lead sponsor
Euresist Network GEIE
Collaborators
Karolinska Institutet, Centro Hospitalar Lisboa Ocidental, Heinrich-Heine University, Duesseldorf, ASST Santi Paolo e Carlo, Imperial College London, Vilnius University Hospital Santaros Klinikos, University of Rome Tor Vergata, Bach Mai Hospital, Kenya Medical Research Institute, Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasus", University Hospitals Dorset NHS Foundation Trust
Responsible party
Sponsor
First posted
Jul 19, 2022
Start date
Feb 23, 2022
Primary completion
Oct 13, 2026 (estimated)
Completion
Oct 13, 2026 (estimated)
Last update
Aug 29, 2024

Study contacts

FRANCESCA INCARDONA Project Coordinator
Contact
francesca.incardona@euresist.org
+393356112830
ANDERS Sönnerborg, Prof
study chair · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion